Quick Answer
Inhibrx Biosciences, Inc. reported Operating Income of -$135.03 million for fiscal year 2025.
Inhibrx Biosciences, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$135.03M | +59.3% |
| 2024 | -$331.45M | -51.2% |
| 2023 | -$219.22M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$33.81M | +27.7% | -23.5% |
| June 30, 2025 | -$27.39M | +83.0% | +36.2% |
| March 31, 2025 | -$42.90M | +41.9% | +8.3% |
| September 30, 2024 | -$46.80M | -2.1% | +70.9% |
| June 30, 2024 | -$160.90M | -289.2% | -117.9% |
| March 31, 2024 | -$73.83M | — | -61.1% |
| September 30, 2023 | -$45.83M | — | -10.9% |
| June 30, 2023 | -$41.34M | — | — |
- Inhibrx Biosciences, Inc. showed an increase of +59.3% in Operating Income compared to the prior fiscal year.
- Over the 2023–2025 period, Inhibrx Biosciences, Inc.’s operating income has grown by 38.4% (from -$219.22 million to -$135.03 million).
- The most recent figure is from Inhibrx Biosciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: